• These were the best performers on the ASX 200 last week

    beat the share market

    The S&P/ASX 200 Index (ASX: XJO) was on form again last week and recorded a very strong gain. The benchmark index climbed 4.2% over the five days to end at 5998.69 points.

    While most shares on the index pushed higher, some climbed more than most. Here’s why these were the best performers on the ASX 200 over the period:

    The Pilbara Minerals Ltd (ASX: PLS) share price was the best performer on the ASX 200 last week with a massive 36.5% gain. This was despite Chinese lithium prices falling to their lowest levels of the year last week amid lacklustre demand for the battery making ingredient. Pilbara Minerals is one of the most shorted shares on the ASX with short interest of 9.25%. I suspect some of its gains could have been down to short sellers buying shares to close their positions.

    The Unibail-Rodamco-Westfield (ASX: URW) share price was on form for once and surged 28% higher last week. This appears to have been driven by optimism over the reopening of economies and bargain hunters taking advantage of a recent collapse in the shopping centre operator’s share price. Even after last week’s gain, Unibail-Rodamco-Westfield’s shares are down 55% from their 52-week high.

    The Adbri Ltd (ASX: ABC) share price was a strong performer last week with a 27.6% gain. The catalyst for this strong gain was the government announcing a $688 million HomeBuilder program to support the construction industry. This program will see Australians offered $25,000 grants to build a new home or start a major renovation. Adbri, previously known as Adelaide Brighton, looks well-placed to benefit as a building materials provider.

    The Perenti Global Ltd (ASX: PRN) share price wasn’t far behind with a 23.5% gain last week. This was despite there being no news out of the mining services company. These latest gains mean that Perenti, formerly known as Ausdrill, has seen its shares rally 225% higher since dropping to a 52-week low in late March.

    The Bendigo and Adelaide Bank Ltd (ASX: BEN) share price caught the eye last week with a 19% gain. Investors were piling into banking shares again on the belief that the sector’s outlook was not as bad as first feared. The big four banks were also strong performers and played a key role in driving the ASX 200 higher.

    Missed out on these gains? Then don’t miss out on these dirt cheap shares before they rebound…

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These were the best performers on the ASX 200 last week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3cBPAjv

  • Novavax’s COVID Vaccine Candidate Left off White House List; 5-Star Analyst Explains the Implications

    Novavax’s COVID Vaccine Candidate Left off White House List; 5-Star Analyst Explains the ImplicationsThe Trump administration picked out five companies it believes are most likely to produce 2020’s holy grail – a vaccine for the coronavirus. Unfortunately, Novavax (NVAX) was not on the list.Although the White House didn’t disclose what lay behind the choices, 5-star B.Riley FBR analyst Mayank Mamtani provided some possible explanations.3 of the choices already have clinical studies in various degrees of progress (Moderna, AstraZeneca/Oxford University and Pfizer/BioNTech), whilst Novavax only began enrollment late last month. This implies to Mamtani that “speed to market entry” could be a major factor in the decision-making process.Whilst “risk diversification and cost sharing,” and a preference for large companies (Johnson & Johnson, Merck) with the necessary balance sheet required to conduct the extensive and pricey vaccine development and manufacturing may also be contributing factors.Even so, while those reasonings might explain the smaller player’s omission, Mamtani maintains Novavax should be added to the list.Mamtani said, “We remain encouraged by the de-risked nature of NVAX's vaccine candidate, on the basis of the most extensive preclinical data generated to date, and now reviewed closely by the global scientific community residing with CEPI, WHO, and SII, as well as U.S. agencies such as CDC, NIH-NIAID, and BARDA. We believe adding NVAX's NVX-CoV2373 on the basis of its proprietary adjuvanted recombinant nanoparticle platform could further help diversify development risk as well as tap into a relatively clearer path to market and manufacturing scale-up that NVAX has made tangible progress on recently…”To this end, Mamtani reiterated a Buy on NVAX and has a $74 price target, indicating the potential for 60% upside over the next year. (To watch Mamtani’s track record, click here)All other 4 analysts to post a Novavax review over the last 3 months recommend the stock a Buy, too. A Strong Buy consensus rating is accompanied by a $49.20 price target, implying room for an 11% uptick in the months ahead. (See Novavax stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/2Xzkip8

  • These were the worst performers on the ASX 200 last week

    man looking down falling line chart, falling share price

    It certainly was a fantastic five days for the S&P/ASX 200 Index (ASX: XJO) last week. The benchmark index stormed 4.2% higher over the period to end at 5998.69 points.

    Not all shares were able to climb higher with the market, though. Here’s why these were the worst performers on the ASX 200:

    The Gold Road Resources Ltd (ASX: GOR) share price was the worst performer on the ASX 200 last week with a 14.4% decline. This was driven by a pullback in the gold price after risk appetite improved. A number of other gold miners including Evolution Mining Ltd (ASX: EVN), Northern Star Resources Ltd (ASX: NST), Saracen Mineral Holdings Limited (ASX: SAR), and Silver Lake Resources Limited (ASX: SLR) were also among the worst performers during the week.

    The Nufarm Limited (ASX: NUF) share price was a poor performer last week and fell 8.9%. This decline appears to have been driven by a broker note out of Macquarie. According to the note, the broker downgraded Nufarm’s shares to an underperform rating with a $4.85 price target. Its analysts were underwhelmed with its trading update and appear concerned over its prospects in the important fourth quarter.

    The Pro Medicus Limited (ASX: PME) share price was out of form and fell 8% over the period. This was despite the healthcare technology company announcing a major contract win. It appears as though a broker note out of UBS offset this good news. The broker downgraded Pro Medicus’ shares to a neutral rating with a $29.65 price target. It made the move on valuation grounds.

    The TPG Telecom Ltd (ASX: TPM) share price wasn’t far behind with a 7.2% decline last week. It looks as though some investors were taking a bit of profit off the table after a strong share price gain over the last month. TPG Telecom’s gain since the beginning of May was driven by optimism over the progress it is making with its merger plans with Vodafone Australia.    

    Need a lift after these declines? Then you won’t want to miss out on the five recommendations below…

    NEW! 5 Cheap Stocks With Massive Upside Potential

    Our experts at The Motley Fool have just released a FREE report detailing 5 shares you can buy now to take advantage of the much cheaper share prices on offer.

    One is a diversified conglomerate trading over 30% off it’s all-time high, all while offering a fully franked dividend yield of over 3%…

    Another is a former stock market darling that is one of Australia’s most popular and iconic businesses. Trading at a significant discount to its 52-week high, not only does this stock offer massive upside potential, but it also trades on an attractive fully franked dividend yield of almost 4%.

    Plus, this free report highlights 3 more cheap bets that could position you to profit in 2020 and beyond.

    Simply click here to scoop up your FREE copy and discover the names of all 5 cheap shares.

    But you will have to hurry because the cheap share prices on offer today might not last for long.

    As of 2/6/2020

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These were the worst performers on the ASX 200 last week appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2UeTMzj

  • Results From Oxford University’s Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand

  • Alcoa CEO Sees No Certainty a Definitive Recovery Is Coming

  • More consumers show interest in traveling on cruises in the near term: Analyst

  • Synovus Financial Corp. Earnings Missed Analyst Estimates: Here’s What Analysts Are Forecasting Now